Amneal Pharmaceuticals (AMRX) Change in Receivables (2017 - 2026)

Amneal Pharmaceuticals' Change in Receivables history runs 10 years deep, the most recent figure standing at -$44.0 million for Q1 2026.

• On a quarterly basis, Change in Receivables fell 108.12% year-over-year to -$44.0 million in Q1 2026; TTM through Mar 2026 was $97.7 million, a 13.19% increase from a year earlier, with the FY2025 full-year figure at $120.6 million, down 25.87% from the prior year.
• Change in Receivables retreated to -$44.0 million in Q1 2026 per AMRX's latest filing, from $10.3 million in the prior quarter.
• Across five years, Change in Receivables topped out at $150.8 million in Q2 2022 and bottomed at -$196.0 million in Q1 2023.
• The 5-year median for Change in Receivables is $17.9 million (2023), against an average of $11.3 million.
• Across the five-year window, Change in Receivables plunged 221.71% in 2024 and surged 455.83% in 2025, its largest moves.
• Year by year, Change in Receivables stood at $113.3 million in 2022, then tumbled by 168.18% to -$77.2 million in 2023, then surged by 137.04% to $28.6 million in 2024, then tumbled by 63.86% to $10.3 million in 2025, then sank by 525.74% to -$44.0 million in 2026.
• Per Business Quant, the three latest AMRX Change in Receivables figures stand at -$44.0 million (Q1 2026), $10.3 million (Q4 2025), and $77.6 million (Q3 2025).